oleanolic acid has been researched along with Cardiac Failure in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, L; Feng, ZQ; Hu, KW; Qian, M; Sun, HB; Sun, JZ; Zheng, RN | 1 |
| Capolongo, G; Celentano, S; Pollastro, RM | 1 |
| Gao, L; Hackfort, BT; Tian, C; Zhang, A; Zucker, IH | 1 |
| Toto, RD | 1 |
| Baigent, C; Lennon, R | 1 |
| Bakris, GL; Block, GA; Chertow, GM; Chin, MP; Goldsberry, A; Heerspink, HJL; Inker, LA; Meyer, CJ; O'Grady, M; Pergola, PE; Wanner, C; Warnock, DG | 1 |
| Block, GA; Chertow, GM; Chin, MP; Goldsberry, A; Heerspink, HJL; McCullough, PA; Meyer, CJ; Packham, D; Pergola, PE; Rossing, P; Spinowitz, B; Sprague, SM; Warnock, DG | 1 |
| Bakris, GL; Chin, MP; Linde, PG; McCullough, PA; Meyer, CJ; O'Grady, M; Packham, D; Reisman, SA; Vaziri, ND; Ward, KW; Warnock, DG | 1 |
| Bakris, GL; Chertow, GM; Chin, MP; de Zeeuw, D; Goldsberry, A; Linde, PG; McCullough, PA; McMurray, JJ; Meyer, CJ; Wittes, J; Wrolstad, D | 1 |
| Camer, D; Huang, XF | 2 |
| Chin, MP; Meyer, CJ | 1 |
| Cui, T; Janicki, JS; Li, J; Li, S; Meyer, CJ; Niu, T; Ruiz, S; Tang, D; Wang, W; Wang, XL; Xing, Y; Zhao, Y | 1 |
| Arai, M; Kanda, T; Kobayashi, I; Kurabayashi, M; Nagai, R; Sekiguchi, K; Seta, Y; Tanaka, T; Yokoyama, T | 1 |
1 review(s) available for oleanolic acid and Cardiac Failure
| Article | Year |
|---|---|
[Bardoxolone: a new potential therapeutic agent in the treatment of autosomal dominant polycystic kidney disease?]
Topics: Clinical Trials as Topic; Disease Progression; Down-Regulation; Early Termination of Clinical Trials; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; NF-E2-Related Factor 2; NF-kappa B; Oleanolic Acid; Polycystic Kidney, Autosomal Dominant; Renal Agents | 2019 |
4 trial(s) available for oleanolic acid and Cardiac Failure
| Article | Year |
|---|---|
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
Topics: Aged; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Oleanolic Acid; Renal Dialysis; Treatment Outcome | 2018 |
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Topics: Adult; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Early Termination of Clinical Trials; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oleanolic Acid; Treatment Outcome | 2019 |
Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Topics: Animals; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Heart Failure; Humans; Macaca fascicularis; Male; Oleanolic Acid; Rats; Renal Insufficiency, Chronic; Sodium; Urine; Water-Electrolyte Imbalance | 2014 |
Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Topics: Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Oleanolic Acid; Patient Safety; Predictive Value of Tests; Reference Values; Renal Insufficiency, Chronic; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome | 2014 |
9 other study(ies) available for oleanolic acid and Cardiac Failure
| Article | Year |
|---|---|
Qi-Tai-Suan, an oleanolic acid derivative, ameliorates ischemic heart failure via suppression of cardiac apoptosis, inflammation and fibrosis.
Topics: Animals; Apoptosis; Fibrosis; Heart Failure; Inflammation; Male; Mice; Mice, Inbred C57BL; Myocardial Ischemia; Oleanolic Acid | 2022 |
Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure.
Topics: Animals; Chronic Disease; CREB-Binding Protein; Heart Failure; Hemodynamics; Male; NF-E2-Related Factor 2; NF-kappa B; Oleanolic Acid; Rats; Rats, Sprague-Dawley; Ventricular Function, Left | 2019 |
Bardoxolone-the Phoenix?
Topics: Anti-Inflammatory Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate; Heart Failure; Humans; Nephritis, Hereditary; Oleanolic Acid; Renal Insufficiency, Chronic | 2018 |
Should We Increase GFR with Bardoxolone in Alport Syndrome?
Topics: Albuminuria; Anti-Inflammatory Agents; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate; Heart Failure; Humans; Nephritis, Hereditary; Oleanolic Acid; Renal Insufficiency, Chronic | 2018 |
The endothelin pathway: a protective or detrimental target of bardoxolone methyl on cardiac function in patients with advanced chronic kidney disease?
Topics: Blood Pressure; Cardiovascular System; Clinical Trials, Phase III as Topic; Early Termination of Clinical Trials; Endothelins; Heart; Heart Failure; Humans; Kidney; Kidney Failure, Chronic; Oleanolic Acid | 2014 |
Reply: To PMID 25307295.
Topics: Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Heart Failure; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Is B-type natriuretic peptide a risk factor for heart failure in patients treated with bardoxolone methyl?
Topics: Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Heart Failure; Humans; Male; Oleanolic Acid; Renal Insufficiency, Chronic | 2015 |
Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2.
Topics: Active Transport, Cell Nucleus; Animals; Cell Nucleus; Constriction; Fibrosis; Heart; Heart Failure; Hypertrophy; Male; Mice; Mice, Inbred C57BL; Myocardium; NF-E2-Related Factor 2; Oleanolic Acid; Oxidative Stress; Pressure; Up-Regulation; Ventricular Remodeling | 2012 |
Therapy with the nonpeptide endothelin receptor antagonist 97-139 in a murine model of congestive heart failure: reduction of cardiac mass and myofiber hypertrophy.
Topics: Animals; Caffeic Acids; Cardiomegaly; Endothelin Receptor Antagonists; Female; Heart Failure; Mice; Mice, Inbred DBA; Myocardium; Oleanolic Acid; Organ Size | 2000 |